BOLTON SECURITIES CORPORATION’s Intellia Therapeutics NTLA Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$71	Buy	+10	New	+$101	﹤0.01%	1849

Other funds holding NTLA

ARK Investment Management St. Petersburg, Florida $15.5B AUM 50.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's NTLA Position: Q1 2025 in Review

BOLTON SECURITIES CORPORATION opened a new position in Intellia Therapeutics (NTLA) in Q1 2025: 10 shares worth $71. The stake represents ﹤0.01% of the portfolio and ranks #1849 among its holdings.

297 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

BOLTON SECURITIES CORPORATION held 10 shares of Intellia Therapeutics worth $71 as of Q1 2025.
Intellia Therapeutics was a new BOLTON SECURITIES CORPORATION position in Q1 2025.
Intellia Therapeutics made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q1 2025, its #1849 holding.
297 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2025, filed 12 Nov 2026.